Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.

Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C

Metabolism: clinical and experimental1 Dec 2003Cited by 40 (Europe PMC)

PMID14669170DOI10.1016/j.metabol.2003.06.003PepBankPUB-14669170

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes trial completers, pramlintide reduced HbA1c by a placebo-corrected 0.5% at week 52.
In plain wordsIn type 2 diabetes trial completers, pramlintide reduced HbA1c more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c, pooled completers
Study
n = 410
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
Placebo-corrected HbA1c treatment effect at week 52
−0.5%
pooled completers
Source sentences
Summary
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917001
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes trial completers, pramlintide reduced weight by a placebo-corrected 2.6 kg at week 52.
In plain wordsIn type 2 diabetes trial completers, pramlintide reduced weight more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight, pooled completers
Study
n = 410
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
Placebo-corrected body weight treatment effect at week 52
−2.6 kg
pooled completers
Source sentences
Summary
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917002
03HumanRandomized controlled trialEfficacy outcome
In Caucasians with insulin-treated type 2 diabetes, pramlintide treatment was associated with a HbA1c reduction of 0.5% at week 52.
In plain wordsIn Caucasians with type 2 diabetes, HbA1c fell by 0.5% at week 52 with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c, Caucasians
Study
n = 315
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
HbA1c change at week 52
−0.5%
Caucasians
Source sentences
Summary
The simultaneous reduction in A(1C) and body weight at week 52 was evident across all 3 ethnic groups and appeared to be most pronounced in African Americans (-0.7%, -4.1 kg), followed by Caucasians (-0.5%, -2.4 kg) and Hispanics (-0.3%, -2.3 kg).
3 context sentences(design, population, supporting numbers)
Summary · context
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917005
04HumanRandomized controlled trialEfficacy outcome
In Caucasians with insulin-treated type 2 diabetes, pramlintide treatment was associated with a weight reduction of 2.4 kg at week 52.
In plain wordsIn Caucasians with type 2 diabetes, weight fell by 2.4 kg at week 52 with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight, Caucasians
Study
n = 315
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
weight change at week 52
−2.4 kg
Caucasians
Source sentences
Summary
The simultaneous reduction in A(1C) and body weight at week 52 was evident across all 3 ethnic groups and appeared to be most pronounced in African Americans (-0.7%, -4.1 kg), followed by Caucasians (-0.5%, -2.4 kg) and Hispanics (-0.3%, -2.3 kg).
3 context sentences(design, population, supporting numbers)
Summary · context
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917006
05HumanRandomized controlled trialEfficacy outcome
In Hispanics with insulin-treated type 2 diabetes, pramlintide treatment was associated with a HbA1c reduction of 0.3% at week 52.
In plain wordsIn Hispanics with type 2 diabetes, HbA1c fell by 0.3% at week 52 with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c, Hispanics
Study
n = 48
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
HbA1c change at week 52
−0.3%
Hispanics
Source sentences
Summary
The simultaneous reduction in A(1C) and body weight at week 52 was evident across all 3 ethnic groups and appeared to be most pronounced in African Americans (-0.7%, -4.1 kg), followed by Caucasians (-0.5%, -2.4 kg) and Hispanics (-0.3%, -2.3 kg).
3 context sentences(design, population, supporting numbers)
Summary · context
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917007
06HumanRandomized controlled trialEfficacy outcome
In Hispanics with insulin-treated type 2 diabetes, pramlintide treatment was associated with a weight reduction of 2.3 kg at week 52.
In plain wordsIn Hispanics with type 2 diabetes, weight fell by 2.3 kg at week 52 with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight, Hispanics
Study
n = 48
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
weight change at week 52
−2.3 kg
Hispanics
Source sentences
Summary
The simultaneous reduction in A(1C) and body weight at week 52 was evident across all 3 ethnic groups and appeared to be most pronounced in African Americans (-0.7%, -4.1 kg), followed by Caucasians (-0.5%, -2.4 kg) and Hispanics (-0.3%, -2.3 kg).
3 context sentences(design, population, supporting numbers)
Summary · context
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917008
07HumanRandomized controlled trialEfficacy outcome
In African Americans with insulin-treated type 2 diabetes, pramlintide treatment was associated with a HbA1c reduction of 0.7% at week 52.
In plain wordsIn African Americans with type 2 diabetes, HbA1c fell by 0.7% at week 52 with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c, African Americans
Study
n = 47
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
HbA1c change at week 52
−0.7%
African Americans
Source sentences
Summary
The simultaneous reduction in A(1C) and body weight at week 52 was evident across all 3 ethnic groups and appeared to be most pronounced in African Americans (-0.7%, -4.1 kg), followed by Caucasians (-0.5%, -2.4 kg) and Hispanics (-0.3%, -2.3 kg).
3 context sentences(design, population, supporting numbers)
Summary · context
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917003
08HumanRandomized controlled trialEfficacy outcome
In African Americans with insulin-treated type 2 diabetes, pramlintide treatment was associated with a weight reduction of 4.1 kg at week 52.
In plain wordsIn African Americans with type 2 diabetes, weight fell by 4.1 kg at week 52 with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight, African Americans
Study
n = 47
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
weight change at week 52
−4.1 kg
African Americans
Source sentences
Summary
The simultaneous reduction in A(1C) and body weight at week 52 was evident across all 3 ethnic groups and appeared to be most pronounced in African Americans (-0.7%, -4.1 kg), followed by Caucasians (-0.5%, -2.4 kg) and Hispanics (-0.3%, -2.3 kg).
3 context sentences(design, population, supporting numbers)
Summary · context
Collectively, pramlintide-treated patients achieved significant reductions from baseline in both A(1C) and body weight (placebo-corrected treatment effects at week 52: -0.5% and -2.6 kg, respectively, both P <.0001).
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917004
09HumanRandomized controlled trialSafety outcome
In type 2 diabetes trial completers, hypoglycemia incidence did not increase with pramlintide versus placebo, at 43% versus 40%.
In plain wordsIn type 2 diabetes trial completers, hypoglycemia incidence did not increase with pramlintide versus placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHypoglycemia incidence
Study
n = 410
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
Hypoglycemia incidence
43%
pramlintide
Hypoglycemia incidence
40%
placebo
Source sentences
Summary
The glycemic improvement with pramlintide was not associated with an increased incidence of hypoglycemia over the entire study period (43% pramlintide v 40% placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917009
10HumanRandomized controlled trialSafety outcome
In type 2 diabetes trial completers, nausea occurred in 25% with pramlintide versus 16% with placebo, mostly mildly and early.
In plain wordsIn type 2 diabetes trial completers, nausea was more frequent with pramlintide than placebo and was mostly mild and early.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseNausea
Study
n = 410
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
120 microg twice daily or 150 microg 3 times a day · 52 weeksAs given in this study (human).
Measurements
Nausea incidence
25%
pramlintide
Nausea incidence
16%
placebo
Source sentences
Summary
Nausea, the most common adverse event associated with pramlintide treatment, was mostly mild and confined to the first 4 weeks of therapy (25% pramlintide v 16% placebo) with comparable patterns in the 3 ethnic groups.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of pramlintide in various ethnic groups with type 2 diabetes using insulin, we conducted a pooled post hoc analysis of the 2 trials, which included all Caucasian (n = 315), African American (n = 47), and Hispanic (n = 48) patients
Summary · context
Primary endpoints included changes from baseline to week 52 in A(1C) and body weight.
Report a problemFND-1466917010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.